BLAINTRAMUSCULARVIALPriority Review
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
5/8 — Partial
Priority Review
SYNAGIS (palivizumab) by Swedish Orphan Biovitrum is fusion protein inhibitors [moa]. Approved for respiratory syncytial virus infection, bronchopulmonary dysplasia, congenital heart disease and 1 more indications. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNAGIS (palivizumab) is a monoclonal antibody that inhibits the respiratory syncytial virus (RSV) fusion protein, preventing viral entry into respiratory cells. It is indicated for prophylaxis of serious RSV infection in high-risk pediatric populations, including premature infants, those with bronchopulmonary dysplasia, and children with congenital heart disease. The drug is administered intramuscularly during RSV season to reduce hospitalization risk.
$0.042BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with declining claims volume; career opportunities concentrated in transition planning, market access, and niche pediatric accounts.
Mechanism of Action
Fusion Protein Inhibitors
Pharmacologic Class:
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Worked on SYNAGIS at Swedish Orphan Biovitrum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.